FY 2016 was a year of stabilisation, destocking and some delays to product introductions, especially in China. The outlook for FY 2017 and 2018 is expected to be one of growth, executing on the strategies put in place to exploit the c$2bn hemodynamic monitoring opportunity, particularly in the US, China and Japan. Our forecasts reflect a stable UK business, with upside potential if the company is able to gain greater traction in an underpenetrated high risk surgery market, but with three leve
12 Apr 2016
Positioned for growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positioned for growth
- Published:
12 Apr 2016 -
Author:
Mark Brewer -
Pages:
20
FY 2016 was a year of stabilisation, destocking and some delays to product introductions, especially in China. The outlook for FY 2017 and 2018 is expected to be one of growth, executing on the strategies put in place to exploit the c$2bn hemodynamic monitoring opportunity, particularly in the US, China and Japan. Our forecasts reflect a stable UK business, with upside potential if the company is able to gain greater traction in an underpenetrated high risk surgery market, but with three leve